Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice

Journal of Hypertension

Volumn 29, Issue 2, 2011, Pages 330-338

  Rhaleb, Nour Eddine ^a   Pokharel, Saraswati ^a   Sharma, Umesh ^a   Carretero, Oscar A ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

albuminuria; hypertension; macrophage; N acetyl Ser Asp Lys Pro; nephrin

Indexed keywords

ALBUMIN; COLLAGEN; DEOXYCORTICOSTERONE ACETATE; NEPHRIN; SERASPENIDE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; GLOMERULUS; HYPERTENSION; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION;

EID: 78651295814     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834103ee     Document Type: Article

References (47)

1. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006; 15:152-158.
2. Zoccali C. Endothelial dysfunction and the kidney: emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. J Am Soc Nephrol 2006; 17:S61-S63.
3. Zoccali C, Mallamaci F, Tripepi G. Inflammation and atherosclerosis in endstage renal disease. Blood Purif 2003; 21:29-36.
4. Kelly DJ, Zhang Y, Cox AJ, Gilbert RE. Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model. Kidney Int 2006; 69:1954-1960.
5. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006; 332:1426-1431.
6. Shibuya K, Kanasaki K, Isono M, Sato H, Omata M, Sugimoto T, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes 2005; 54:838-845.
7. Kriz W, Lehir M. Pathways to nephron loss starting from glomerular diseases: insights from animal models. Kidney Int 2005; 67:404-419.
8. Ruotsalainen V, Ljungberg P, Wartiovaara J, Lenkkeri U, Kestilä M, Jalanko H, et al. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci USA 1999; 96:7962-7967.
9. Kawashi H, Koike H, Kurihara H, Yaoita E, Orikasa M, Shia MA, et al. Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states. Kidney Int 2000; 57:1949-1961.
10. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001; 44:874-877.
11. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99:342-348.
12. Cavasin MA, Rhaleb NE, Yang XP, Carretero OA. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 2004; 43:1140-1145.
13. Junot C, Nicolet L, Ezan E, Gonzales M-F, Menard J, Azizi M. Effects of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats. J Cardiovasc Pharmacol 1999; 291:982-987.
14. Liu J, Ormsby A, Oja-Tebbe N, Pagano PJ. Gene transfer of NAD(P)H oxidase inhibitor to the vascular adventitia attenuates medial smooth muscle hypertrophy. Circ Res 2004; 95:587-594.
15. Pokharel S, Van Geel PP, Sharma UC, Cleutjens JPM, Bohnemeier H, Tian X-L, et al. Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation 2004; 110:3129-3135.
16. Azizi M, Rousseau A, Ezan E, Guyene T-T, Michelet S, Grognet J-M, et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996; 97:839-844.
17. Azizi M, Ezan E, Nicolet L, Grognet JM, Menard J. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensinconverting enzyme inhibition. Hypertension 1997; 30:1015-1019.
18. Rasoul S, Carretero OA, Peng H, Cavasin MA, Zhuo J, Sanchez-Mendoza A, et al. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J Hypertens 2004; 22:593-603.
19. Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997; 52:1593-1601.
20. Gilbert RE, Wu LL, Kelly DJ, Cox A, Wilkinson-Berka JL, Johnston CI, et al. Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol 1999; 155:429-440.
21. Liao T-D, Yang X-P, D'ambrosio M, Zhang Y, Rhaleb N-E, Carretero OA. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass. Hypertension 2010; 55:459-467.
22. Rhaleb N-E, Peng H, Alfie M, Shesely EG, Carretero OA. Effect of ACE inhibitor on DOCA-salt- and aortic coarctation-induced hypertension in mice. Do kinin B2 receptors play a role? Hypertension 1999; 33:329-334.
23. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 1995; 25:1111-1115.
24. Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 1995; 147:325-338.
25. Brown L, Duce B, Miric G, Sernia C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol 1999; 10:S143-S148.
26. Melhem MF, Craven PA, Liachenko J, Derubertis FR. Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J Am Soc Nephrol 2002; 13:108-116.
27. Davis BJ, Cao Z, De Gasparo M, Kawachi H, Cooper ME, Allen TJ. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens 2003; 21:209-216.
28. Peng H, Carretero OA, Raij L, Yang F, Kapke A, Rhaleb N-E. Antifibrotic effects of N-acetyl-seryl-aspartyl-lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension 2001; 37:794-800.
29. Ni W, Lookingland K, Watts SW. Arterial 5-hydroxytryptamine transporter function is impaired in deoxycorticosterone acetate and nomega-nitro-Larginine but not spontaneously hypertensive rats. Hypertension 2006; 48:134-140.
30. Peng H, Carretero OA, Alfie ME, Masura JA, Rhaleb N-E. Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene. Hypertension 2001; 37:974-980.
31. Landmesser U, Dikalov S, Price SR, Mccann L, Fukai T, Holland SM, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111:1201-1209.
32. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77:1993-2000.
33. Peng H, Carretero OA, Brigstock DR, Oja-Tebbe N, Rhaleb N-E. Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension. Hypertension 2003; 42:1164-1170.
34. Blasi ER, Rocha R, Rudolph AE, Blomme EAG, Polly ML, Mcmahon EG. Aldosterone/salt reduces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63:1791-1800.
35. Hpetinstall RH, Hill GS. Steroid-induced hypertension in the rat. A study of the effects of renal artery constriction on hypertension caused by deoxycorticosterone. Lab Invest 1967; 16:751-767.
36. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001; 37:781-786.
37. Rodriguez-Iturbe B, Quiroz Y, Kim CH, Vaziri ND. Hypertension induced by aortic coarctation above the renal arteries is associated with immune cell infiltration of the kidneys. Am J Hypertens 2005; 18:1449-1456.
38. Yang F, Yang X-P, Liu Y-H, Xu J, Cingolani O, Rhaleb N-E, et al. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 2004; 43:229-236.
39. Rhaleb N-E, Peng H, Yang X-P, Liu Y-H, Mehta D, Ezan E, et al. Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension. Circulation 2001; 103:3136-3141.
40. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, et al. Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994; 24:195-204.
41. Ohta K, Kim S, Hamaguchi A, Yukimura T, Miura K, Takaori K, et al. Role of angiotensin II in extracellular matrix and transforming growth factor-beta 1 expression in hypertensive rats. Eur J Pharmacol 1994; 269:115-119.
42. Lijnen PJ, Petrov VV, Fagard RH. Association between transforming growth factor-b and hypertension. Am J Hypertens 2003; 16:604-611.
43. Manning RD Jr, Meng S, Tian N. Renal and vascular oxidative stress and salt-sensitivity of arterial pressure. Acta Physiol Scand 2003; 179:243-250.
44. Zughaier SM, Shafer WM, Stephens DS. Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell Microbiol 2005; 7:1251-1262.
45. Pokharel S, Rasoul S, Roks AJ, van Leeuwen RE, van Luyn MJA, Deelman LE, et al. N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension 2002; 40:155-161.
46. Kanasaki K, Koya D, Sugimoto T, Isono M, Kashiwagi A, Haneda M. N-acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-b-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J Am Soc Nephrol 2003; 14:863-872.
47. Rhaleb N-E, Peng H, Harding P, Tayeh M, Lapointe MC, Carretero OA. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts. Hypertension 2001; 37:827-832.